Compare · APLM vs NVS
APLM vs NVS
Side-by-side comparison of Apollomics Inc. (APLM) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLM and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $280.65B, about 7303.6x APLM ($38.4M).
- Over the past year, APLM is up 104.1% and NVS is up 27.1% - APLM leads by 77.1 points.
- APLM has been more active in the news (8 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for APLM).
- Company
- Apollomics Inc.
- Novartis AG
- Price
- $13.37-3.05%
- $147.06-2.50%
- Market cap
- $38.4M
- $280.65B
- 1M return
- +2.77%
- -2.24%
- 1Y return
- +104.12%
- +27.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 1
- Recent ratings
- 0
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest APLM
- Chief Financial Officer Lin Peter Kuan-How converted options into 10,000 units of CLASS A ORDINARY SHARES and covered exercise/tax liability with 3,588 units of CLASS A ORDINARY SHARES, increasing direct ownership by 40% to 22,312 units (SEC Form 4)
- Chief Executive Officer Chen Hung-Wen converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 3% to 148,334 units (SEC Form 4)
- Director Chu Yi-An converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Director Chen Hong-Jung converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 16% to 3,620 units (SEC Form 4)
- Director Tsai Hsien-Shu converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Chief Operating Officer Chen Yi-Kuei converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 15,000 units (SEC Form 4)
- Director Jan Chen-Huan converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- SEC Form EFFECT filed by Apollomics Inc.
- Director Huang Ya-Chi converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 100% to 1,000 units (SEC Form 4)
- Amendment: SEC Form F-3/A filed by Apollomics Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG